Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
AMIDATE vs FLUOTHANE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
AMIDATE (etomidate) is a nonbarbiturate hypnotic agent that acts as a positive allosteric modulator of the GABA-A receptor at the beta-2/3 subunit, enhancing the inhibitory effects of GABA and producing rapid sedation and anesthesia.
Halothane enhances GABA-A receptor activity and inhibits NMDA receptors, leading to neuronal hyperpolarization and decreased excitability. It also potentiates glycine receptor function and disrupts synaptic transmission via interaction with voltage-gated sodium channels.
Induction of general anesthesia,Maintenance of anesthesia (as part of balanced anesthesia),Procedural sedation (off-label),Rapid sequence intubation (RSI) (off-label)
Induction and maintenance of general anesthesia,Off-label: Use for status asthmaticus (rarely)
0.2-0.6 mg/kg IV bolus for induction of anesthesia.
Induction: 0.5-3% halothane in oxygen or nitrous oxide/oxygen; maintenance: 0.5-1.5%.
Terminal elimination half-life: 2.5–4 hours (adults); 1–2 hours (children); Prolonged in hepatic impairment or with continuous infusion.
Terminal elimination half-life is biphasic: initial 2-5 minutes (rapid redistribution), terminal 15-20 hours for trace amounts in adipose tissue due to slow release; contextually, emergence from anesthesia occurs within minutes.
Primarily hepatic via hydrolysis by esterases to inactive metabolites (carboxylic acid and ethanol); also undergoes glucuronidation.
Hepatic metabolism via cytochrome P450 enzymes (CYP2E1 major, CYP2A6 minor) to trifluoroacetic acid, chloride, and bromide ions; reductive metabolism under hypoxic conditions produces potentially hepatotoxic intermediates.
Renal: <5% unchanged; Hepatic metabolism to carboxylic acid metabolite (inactive); Metabolite renally eliminated; Fecal: negligible.
Primarily exhaled unchanged via the lungs; negligible renal (0.5% as metabolites) and fecal elimination.
97–98% bound; Primary binding to albumin; Reduced binding in neonates and hepatic/renal disease.
~40-50% bound to albumin.
Vd: 2.5–4.5 L/kg; Large Vd indicates extensive tissue distribution (highly lipophilic).
2-5 L/kg; indicates extensive tissue distribution, particularly in adipose and brain.
IV: 100%; IM: >90%; Rectal: ~50% (variable).
Inhalation: 100% (administered as gas); no other relevant routes.
No adjustment required; pharmacokinetics unchanged in renal impairment.
No dose adjustment required for renal impairment; halothane is minimally excreted renally.
No specific guidelines; use with caution in severe hepatic impairment due to potential for decreased clearance.
Contraindicated in patients with Child-Pugh class B or C cirrhosis due to risk of hepatotoxicity; use with caution in mild impairment with reduced doses.
3-5 mg/kg IV bolus for induction in children; lower doses may be sufficient.
Induction: 0.5-2% halothane in oxygen; maintenance: 0.3-1%. Dose based on response.
Reduce dose to 0.15-0.3 mg/kg IV bolus due to increased sensitivity and decreased clearance.
Reduce induction concentration to 0.5-1% and maintenance to 0.5% due to increased sensitivity and slower clearance.
None
Halothane is associated with a risk of life-threatening hepatic injury, including fatal hepatic necrosis, primarily following repeated exposure or in patients with known hypersensitivity. It should be avoided in patients with a history of unexplained jaundice or fever after halothane administration.
Suppresses adrenal steroidogenesis via reversible inhibition of 11-beta-hydroxylase (cortisol and aldosterone synthesis) – risk of adrenal insufficiency, especially with prolonged infusion or multiple doses,May cause myoclonus (involuntary muscle movements) during induction,Can produce hypotension less frequently than other induction agents, but still possible,Use caution in patients with adrenal suppression, sepsis, or hepatic impairment,May cause pain on injection (use large vein or consider pretreatment)
Risk of hepatic necrosis (especially with repeated use); malignant hyperthermia; respiratory depression; hypotension; cardiac arrhythmias (including sensitization to catecholamines); increased intracranial pressure; requires trained personnel and monitoring; use caution in patients with hepatic disease.
Known hypersensitivity to etomidate or any component of the formulation,Patients with known adrenal insufficiency (relative contraindication due to potential for further suppression)
Known hypersensitivity to halothane or other halogenated anesthetics; history of unexplained jaundice or fever after halothane administration; suspected or known hepatic injury from halogenated anesthetics; risk of malignant hyperthermia (including family history).
None known. However, because etomidate is administered intravenously in a fasting state prior to procedures, food intake is restricted per standard pre-procedural fasting guidelines (typically NPO for 6-8 hours).
No specific food interactions known, but fasting is required preoperatively to prevent aspiration pneumonitis caused by relaxation of the lower esophageal sphincter and loss of airway reflexes.
Pregnancy Category D. First trimester: Associated with congenital anomalies (e.g., neural tube defects, cardiovascular malformations) based on human data. Second/third trimesters: May cause fetal CNS depression, hypotonia, and respiratory depression with chronic use. Avoid in pregnancy unless benefit outweighs risk.
FDA Pregnancy Category C. First trimester: Increased risk of congenital anomalies (cleft palate, skeletal defects) in animal studies; avoid unless essential. Second and third trimesters: Prolonged exposure may cause neonatal respiratory depression, hypotonia, and thermoregulatory instability; risk of fetal hypoxia due to maternal hypotension.
Excreted in breast milk; M/P ratio 0.5-0.8. Potential for infant sedation and respiratory depression. Caution advised; monitor infant for drowsiness and feeding difficulties. Consider alternative therapies.
Halothane is excreted in breast milk in low concentrations. M/P ratio not determined. Short-term use is considered compatible with breastfeeding; avoid prolonged or repeated exposure. Monitor infant for sedation and feeding difficulties.
No standard dose adjustment recommended; however, increased clearance during pregnancy may necessitate higher doses for efficacy. Monitor therapeutic response and adjust as needed. Avoid use in first trimester if possible.
Increased sensitivity to myocardial depression; reduce dose by 25-50% in pregnant patients. Monitor closely for hypotension. No specific pharmacokinetic adjustments required due to pregnancy, but consider decreased MAC (minimum alveolar concentration) in late pregnancy.
Amidate (etomidate) is an ultra-short acting non-barbiturate hypnotic used for induction of anesthesia and for procedural sedation. Key pearls: (1) Single dose causes adrenal suppression via 11β-hydroxylase inhibition; avoid continuous infusion or repeated doses. (2) Preferred for hemodynamically unstable patients due to minimal cardiovascular depression. (3) High incidence of myoclonus and pain on injection; pretreat with opioid or benzodiazepine to reduce myoclonus. (4) Contraindicated in porphyria. (5) Rapid onset (30-60 sec) and short duration (3-5 min) limit use to induction only.
Halothane is a potent inhalational anesthetic with low blood-gas solubility, allowing rapid induction and emergence. It sensitizes the myocardium to catecholamines, increasing risk of arrhythmias, especially with epinephrine use. Halothane can cause hepatic necrosis, particularly with repeated exposure (halothane hepatitis). Avoid in patients with unexplained jaundice after prior halothane use. Use low concentrations with spontaneous ventilation to prevent respiratory depression.
This medication is given only by a healthcare professional in a hospital or clinic setting.,You may experience involuntary muscle movements (myoclonus) or pain at the injection site.,Tell your doctor if you have adrenal gland problems, porphyria, or if you are pregnant or breastfeeding.,The effects are short-lived; you will be monitored closely during and after administration.,Do not drive or operate machinery for at least 24 hours after receiving this medication.
Avoid food or drink for at least 6-8 hours before surgery to reduce aspiration risk.,Report any history of liver disease or allergic reactions to anesthesia.,You may experience shivering or nausea after waking up from anesthesia.,Do not drive or operate machinery for at least 24 hours after anesthesia.,Inform your doctor if you notice yellowing of skin or eyes, dark urine, or severe fatigue after surgery.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about AMIDATE vs FLUOTHANE, answered by our medical review team.
AMIDATE is a General Anesthetic that works by AMIDATE (etomidate) is a nonbarbiturate hypnotic agent that acts as a positive allosteric modulator of the GABA-A receptor at the beta-2/3 subunit, enhancing the inhibitory effects of GABA and producing rapid sedation and anesthesia.. FLUOTHANE is a General Anesthetic that works by Halothane enhances GABA-A receptor activity and inhibits NMDA receptors, leading to neuronal hyperpolarization and decreased excitability. It also potentiates glycine receptor function and disrupts synaptic transmission via interaction with voltage-gated sodium channels.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between AMIDATE and FLUOTHANE depend on the specific clinical indication. These are both General Anesthetic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of AMIDATE is: 0.2-0.6 mg/kg IV bolus for induction of anesthesia.. The standard adult dose of FLUOTHANE is: Induction: 0.5-3% halothane in oxygen or nitrous oxide/oxygen; maintenance: 0.5-1.5%.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between AMIDATE and FLUOTHANE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. AMIDATE is classified as Category C. Pregnancy Category D. First trimester: Associated with congenital anomalies (e.g., neural tube defects, cardiovascular malformations) based on human data. Second/third trimesters: . FLUOTHANE is classified as Category C. FDA Pregnancy Category C. First trimester: Increased risk of congenital anomalies (cleft palate, skeletal defects) in animal studies; avoid unless essential. Second and third trime. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.